C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totalling 14,540,000 shares, an increase of 9.7% from the May 31st total of 13,260,000 shares. Based on an average trading volume of 1,430,000 shares, the short-interest ratio is presently 10.2 days.
C4 Therapeutics Trading Up 5.0 %
Shares of CCCC stock opened at $4.85 on Tuesday. The stock has a 50 day moving average of $5.43 and a 200-day moving average of $6.66. C4 Therapeutics has a 12 month low of $1.06 and a 12 month high of $11.88.
C4 Therapeutics (NASDAQ:CCCC – Get Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.41). C4 Therapeutics had a negative net margin of 629.24% and a negative return on equity of 52.85%. The company had revenue of $3.04 million for the quarter, compared to analyst estimates of $10.93 million. As a group, sell-side analysts expect that C4 Therapeutics will post -1.56 EPS for the current fiscal year.
Analysts Set New Price Targets
Get Our Latest Analysis on CCCC
Hedge Funds Weigh In On C4 Therapeutics
Hedge funds have recently made changes to their positions in the business. Headlands Technologies LLC bought a new stake in C4 Therapeutics in the fourth quarter valued at about $39,000. FNY Investment Advisers LLC acquired a new position in shares of C4 Therapeutics in the 4th quarter worth approximately $49,000. Entropy Technologies LP bought a new position in shares of C4 Therapeutics during the 1st quarter worth approximately $126,000. Tower Research Capital LLC TRC boosted its stake in C4 Therapeutics by 33.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 16,322 shares of the company’s stock valued at $92,000 after buying an additional 4,063 shares in the last quarter. Finally, Caxton Associates LP bought a new stake in C4 Therapeutics in the first quarter valued at $172,000. Institutional investors and hedge funds own 78.81% of the company’s stock.
C4 Therapeutics Company Profile
C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.
Featured Articles
- Five stocks we like better than C4 Therapeutics
- ESG Stocks, What Investors Should Know
- Snowflake Stock Rebounds, Flies Higher on AI Spending
- What is a SEC Filing?
- Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks
- Investing in Travel Stocks Benefits
- Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.